Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 11,819 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tablet Clear all
Completed Early Phase 1 Interventional

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

NCT03845881
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Oxycodone, Placebo Oral Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 18, 2026, 2:26 AM EDT
Terminated Phase 3 Interventional Results available

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

NCT01345630
View directory record Official record
Conditions
HIV-1
Interventions
Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, placebo for emtricitabine/tenofovir, placebo for maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
84
States / cities
Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

NCT05806567
View directory record Official record
Conditions
Immune System Disorder, Healthy Volunteers
Interventions
Belumosudil, UGT1A1 victim drug, P-gp victim drug, OATP1B1/BCRP victim drug
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 18, 2026, 2:26 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks

NCT07752407
View directory record Official record
Conditions
Symptomatic Non-erosive Gastroesophageal Reflux Disease
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Mentor, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Results available

Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

NCT00492336
View directory record Official record
Conditions
Schizophrenia
Interventions
rasagiline (Pharmacodynamics), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg

NCT00649129
View directory record Official record
Conditions
Healthy
Interventions
Oxybutynin Chloride ER Tablets 10 mg, Ditropan XL® Tablets 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

NCT00410202
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Entecavir, Tenofovir, Adefovir, Lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

NCT02799602
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
58
States / cities
Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

NCT02125877
View directory record Official record
Conditions
Chronic Iron Overload Due to Transfusion-dependant Anemias
Interventions
Deferasirox dispersible tablet, Defearisox film-coated tablet
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Orange, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

NCT05409911
View directory record Official record
Conditions
Hepatic Impairment
Interventions
S-217622
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Results available

Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease

NCT01587651
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel Loading Dose, Prasugrel Maintenance Dose, Ticagrelor Maintenance Dose
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 74 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Jacksonville, Florida • Miami, Florida • Port Orange, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 4 Interventional

PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia

NCT02598453
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
60
States / cities
Montgomery, Alabama • Lake Havasu City, Arizona • Paradise Valley, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 2:26 AM EDT
Terminated Phase 4 Interventional

Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance

NCT03574857
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure Acute, Cardiovascular Diseases
Interventions
Metolazone Oral Tablet, Chlorothiazide Injection
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.

NCT00727857
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone and metformin, Pioglitazone, Metformin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
66
States / cities
Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2011 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

NCT03811912
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, CTP-543 Matching Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
10
States / cities
Irvine, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

NCT01173601
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Irvine, California • La Habra, California • Redlands, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 3 Interventional

Treatment of Erectile Dysfunction - Long Term Safety and Efficacy

NCT01065012
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Udenafil 50 mg, Udenafil 100 mg, Udenafil 150 mg, Placebo Matching 50 mg Udenafil, Placebo Matching 100 mg Udenafil, Placebo Matching 150 mg Udenafil
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
19 Years and older · Male only
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
72
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 65 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Results available

Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes

NCT00770367
View directory record Official record
Conditions
Diabetes
Interventions
Pioglitazone then Placebo, Placebo then Pioglitazone
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 18, 2026, 2:26 AM EDT
Recruiting Phase 2 Interventional

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

NCT03541928
View directory record Official record
Conditions
High-risk Prostate Cancer, Prostate Cancer
Interventions
HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 18, 2026, 2:26 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

NCT06767683
View directory record Official record
Conditions
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions
ALKS 2680, 4mg, ALKS 2680, 6mg, ALKS 2680, 8mg, ALKS 2680, 10mg, ALKS 2680, 14mg, ALKS 2680, 18mg
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
34
States / cities
Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

NCT00927394
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 18, 2026, 2:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

NCT00601302
View directory record Official record
Conditions
Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions
Amlodipine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 18, 2026, 2:26 AM EDT
Recruiting Phase 2 Interventional

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07298395
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
ENV-294, Placebo
Drug
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 2:26 AM EDT
Terminated Phase 2Phase 3 Interventional

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

NCT01908192
View directory record Official record
Conditions
Schizophrenia
Interventions
NaBen®, Placebo
Drug
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
20
States / cities
Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 18, 2026, 2:26 AM EDT